Market Overview:
The global glioblastoma multiforme treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of glioblastoma multiforme, rising demand for better and advanced treatment options, and growing awareness about glioblastoma multiforme. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the bevacizumab (Avastin) segment accounted for a major share of the global glioblastoma multiforme treatment market in 2017. This segment is projected to grow at a CAGR of 7.8% from 2018 to 2030 due to its high efficacy in treating glioblastoma multiforme tumors.
Product Definition:
Glioblastoma Multiforme Treatment is a cancer treatment that uses radiation therapy and chemotherapy.
Bevacizumab (Avastin):
Bevacizumab (Avastin) is an FDA-approved drug that is used to treat patients with glioblastoma multiforme, a type of brain tumor. The primary factor driving the growth of the Bevacizumab market is its approval by U.S. FDA as a first-line treatment for GBM in 2004 and 2005 respectively.
Carmustine (BiCNU):
Carmustine, also known as 5-aminolevulinic acid; 5-ALA; and BiCNU is an amino acid. It is naturally produced by the body during the process of nerve cell development. However, in some cases it may be given to patients through injections or oral supplements.
Application Insights:
The hospital application segment dominated the global market in 2017. This can be attributed to the availability of advanced healthcare facilities and highly skilled staff, which are capable of handling such cases. Moreover, this treatment is not available anywhere else than a hospital as it requires an intensive care unit for patient management.
Clinic applications are expected to witness lucrative growth over the forecast period due to increasing awareness about glioblastoma multiforme among patients and their families across countries like U.S., Germany, China etc., coupled with rising adoption of diagnostic imaging devices by oncology professionals for early diagnosis of GBM cases in clinics & hospitals worldwide. The others application segment includes research studies and travel abroad for treatment purposes; however, estimates regarding its size were obtained from publicly available databases thus cannot be considered reliable data sources at this time (2017).
Regional Analysis:
North America dominated the global market in 2017. This is due to the increasing incidence of glioblastoma multiforme and rising awareness about available treatment options. In addition, availability of insurance coverage and high healthcare expenditure are some other factors contributing to regional growth. Asia Pacific is expected to witness lucrative growth over the forecast period owing to improving healthcare infrastructure, growing patient awareness levels coupled with economic development in emerging countries such as China & India which will lead towards an increase in demand for GBMs treatment over next eight years.
Key players operating this industry include Roche; Pfizer Inc.
Growth Factors:
- Increasing incidence of Glioblastoma Multiforme (GBM)
- Rising demand for better and advanced treatment options for GBM patients
- Growing awareness about Glioblastoma Multiforme and its treatment options among people
- increasing research and development activities for the development of novel therapies for GBM patients
- Technological advancements in the field of cancer treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Glioblastoma Multiforme Treatment Market Research Report
By Type
Bevacizumab (Avastin), Carmustine (BiCNU), Temozolomide (Temodar and Temodal and Temcad)
By Application
Hospital, Clinic, Others
By Companies
AbbVie, Inc, Activartis GmbH, Agenus Inc, Arog Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, Cortice Biosciences, Exelixis Inc, F. Hoffmann-La Roche Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
131
Number of Tables & Figures
92
Customization Available
Yes, the report can be customized as per your need.
Global Glioblastoma Multiforme Treatment Market Report Segments:
The global Glioblastoma Multiforme Treatment market is segmented on the basis of:
Types
Bevacizumab (Avastin), Carmustine (BiCNU), Temozolomide (Temodar and Temodal and Temcad)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie, Inc
- Activartis GmbH
- Agenus Inc
- Arog Pharmaceuticals, Inc
- Bristol-Myers Squibb Company
- Cavion LLC
- Celldex Therapeutics Inc
- Cortice Biosciences
- Exelixis Inc
- F. Hoffmann-La Roche Ltd.
Highlights of The Glioblastoma Multiforme Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bevacizumab (Avastin)
- Carmustine (BiCNU)
- Temozolomide (Temodar and Temodal and Temcad)
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glioblastoma Multiforme Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for a particular person will vary depending on the specific characteristics of their glioblastoma multiforme tumor. However, some common treatments for glioblastoma multiforme include surgery (to remove the tumor), radiation therapy (which uses high energy beams to kill cancer cells), and chemotherapy (a type of drug that can help shrink tumors).
Some of the major companies in the glioblastoma multiforme treatment market are AbbVie, Inc, Activartis GmbH, Agenus Inc, Arog Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, Cortice Biosciences, Exelixis Inc, F. Hoffmann-La Roche Ltd..
The glioblastoma multiforme treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glioblastoma Multiforme Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glioblastoma Multiforme Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glioblastoma Multiforme Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glioblastoma Multiforme Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glioblastoma Multiforme Treatment Market Size & Forecast, 2020-2028
4.5.1 Glioblastoma Multiforme Treatment Market Size and Y-o-Y Growth
4.5.2 Glioblastoma Multiforme Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Bevacizumab (Avastin)
5.2.2 Carmustine (BiCNU)
5.2.3 Temozolomide (Temodar and Temodal and Temcad)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glioblastoma Multiforme Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glioblastoma Multiforme Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Bevacizumab (Avastin)
9.6.2 Carmustine (BiCNU)
9.6.3 Temozolomide (Temodar and Temodal and Temcad)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Bevacizumab (Avastin)
10.6.2 Carmustine (BiCNU)
10.6.3 Temozolomide (Temodar and Temodal and Temcad)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Bevacizumab (Avastin)
11.6.2 Carmustine (BiCNU)
11.6.3 Temozolomide (Temodar and Temodal and Temcad)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Bevacizumab (Avastin)
12.6.2 Carmustine (BiCNU)
12.6.3 Temozolomide (Temodar and Temodal and Temcad)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Bevacizumab (Avastin)
13.6.2 Carmustine (BiCNU)
13.6.3 Temozolomide (Temodar and Temodal and Temcad)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glioblastoma Multiforme Treatment Market: Competitive Dashboard
14.2 Global Glioblastoma Multiforme Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie, Inc
14.3.2 Activartis GmbH
14.3.3 Agenus Inc
14.3.4 Arog Pharmaceuticals, Inc
14.3.5 Bristol-Myers Squibb Company
14.3.6 Cavion LLC
14.3.7 Celldex Therapeutics Inc
14.3.8 Cortice Biosciences
14.3.9 Exelixis Inc
14.3.10 F. Hoffmann-La Roche Ltd.
